The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
For patients with breast cancer undergoing breast‐conserving surgery (BCS), adjuvant radiation (RT) and hormonal therapy (HT) reduce the risk of locoregional recurrence (LRR). Although several studies have evaluated adjuvant HT ± RT, the outcomes of HT versus RT monotherapy remain less clear. In this study, the risk of LRR is characterized among older patients with early‐stage breast cancer...
Background
Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival (OS) in recurrent glioblastoma (rGBM). The angiopoiein (Ang)–TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase 2, double‐blinded, placebo‐controlled trial of bevacizumab plus trebananib (a novel Fc fusion protein that sequesters Ang1/Ang2) over bevacizumab...
Background
The current study was conducted to evaluate the efficacy and safety of pembrolizumab‐mediated programmed cell death protein 1 inhibition plus radiotherapy (RT) in patients with metastatic triple‐negative breast cancer who were unselected for programmed death‐ligand 1 expression.
Methods
The current study was a single‐arm, Simon 2‐stage, phase 2 clinical trial that enrolled a total of...
BACKGROUND
Angiopoietins contribute to tumor angiogenesis and may be upregulated as a compensatory factor after vascular endothelial growth factor (VEGF) blockade. The authors performed a phase 2 and biomarker study to evaluate trebananib, an angiopoietin 1 and angiopoietin 2 blocking peptibody, with and without bevacizumab in patients with recurrent glioblastoma.
METHODS
Forty‐eight patients who...
BACKGROUND
A 21‐gene expression assay (Oncotype DX recurrence score [RS]) that uses reverse transcriptase‐polymerase chain reaction is used clinically in patients with early‐stage, estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative breast carcinoma (ER+/HER2‐ BC) to determine both prognosis with tamoxifen therapy and the usefulness of adding adjuvant chemotherapy...
BACKGROUNDCabozantinib inhibits mesenchymal‐epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high‐grade glioma.
METHODSCabozantinib doses of 40 mg and...
BACKGROUNDThe prognosis for patients with atypical and malignant meningioma is guarded; whether the extent of resection is associated with survival‐based outcomes in this population remains poorly defined. This study investigated the association between gross total resection (GTR) and all‐cause mortality in patients with atypical and malignant meningioma.
METHODSThe Surveillance, Epidemiology, and...
BACKGROUNDTreatment options for patients with non–small cell lung cancer (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood‐brain barrier–penetrating, microtubule‐targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies in patients with NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases.
METHODSAdult...
Anti‐angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti‐glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given...
BACKGROUNDDespite a high radiographic response rate in patients with recurrent glioblastoma following bevacizumab therapy, survival benefit has been relatively modest. We assess whether tumor volume measurements based on baseline and early posttreatment MRI can stratify patients in terms of progression‐free survival (PFS) and overall survival (OS).
METHODSBaseline (−4 +/‐ 4 days) and posttreatment...
BACKGROUND:The authors sought to improve the toxicity of conventional concurrent chemoradiation therapy for stage III nonsmall cell lung cancer (NSCLC) by using proton‐beam therapy to escalate the radiation dose to the tumor. They report early results of a phase 2 study of high‐dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival.
METHODS:Forty‐four...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.